Transcatheter cerebral embolic protection during WATCHMAN procedure in two patients with persistent left atrial appendage thrombus: Case report with review of the literature.
closure, left atrial appendage
embolic protection devices
embolization, coil/device/transcatheter
structural heart disease intervention
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
23
03
2020
revised:
12
05
2020
accepted:
24
05
2020
pubmed:
17
6
2020
medline:
25
9
2021
entrez:
16
6
2020
Statut:
ppublish
Résumé
Percutaneous left atrial appendage closure (LAAC) has been increasingly used in patients with atrial fibrillation who are poor candidates for long-term oral anticoagulation. The presence of a left atrial appendage (LAA) thrombus is a contraindication for percutaneous LAAC. Despite oral anticoagulation, persistent thrombus is not uncommon. We describe the use of transcatheter cerebral embolic protection with the Sentinel cerebral protection system during LAAC using WATCHMAN in two atrial fibrillation patients who had persistent LAA thrombus despite oral anticoagulation.
Types de publication
Case Reports
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-368Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988-1998.
Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy. J Am Coll Cardiol. 2014;64(1):1-12.
WATCHMAN United States Food and Drug Administration Approval (2020). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130013. Accessed: May 5, 2020.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-132.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.
Ghanem A, Müller A, Nähle CP, et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation. J Am Coll Cardiol. 2010;55(14):1427-1432.
Naber CK, Ghanem A, Abizaid AA, et al. First-in-man use of a novel embolic protection device for patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2012;8(1):43-50.
van Mieghem NM, el Faquir N, Rahhab Z, et al. Incidence and predictors of debris Embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015;8(5):718-724.
Haussig S, Mangner N, Dwyer MG, et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA. 2016;316(6):592-601.
Meincke F, Spangenberg T, Kreidel F, et al. Rationale of cerebral protection devices in left atrial appendage occlusion: cerebral protection in LAA occlusion. Cathet Cardiovasc Interv. 2017;89(1):154-158.
WATCHMAN Left atrial appendage closure device (2020). https://www.watchman.com/en-us-hcp/clinical-evidence/proven-safety.html Accessed March 21, 2020.
Niku AD, Shiota T, Siegel RJ, Rader F. Prevalence and resolution of left atrial thrombus in patients with nonvalvular atrial fibrillation and flutter with oral anticoagulation. Am J Cardiol. 2019;123(1):63-68.
Meincke F, Kreidel F, von Wedel J, Schäfer U, Kuck K-H, Bergmann MW. Percutaneous left atrial appendage closure in patients with left atrial appendage thrombus. EuroIntervention. 2015;10(11):1208.
Tarantini G, D'Amico G, Latib A, et al. Percutaneous left atrial appendage occlusion in patients with atrial fibrillation and left appendage thrombus: feasibility, safety and clinical efficacy. EuroIntervention. 2018;13(13):1595-1602.
Beneduce A, Ancona F, Marzi A, et al. Percutaneous treatment of persistent left atrial appendage thrombus using watchman FLX no-touch implantation technique and cerebral protection system. JACC: Clin Electrophysiol. 2019;5(10):1231-1232.